AstraZeneca (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197